Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 29
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Rocket Pharmaceuticals Inc
RCKT
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$2.42
-0.16
-6.05%
Últ. Act.: Oct 29, 4:10 AM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Rocket Pharmaceuticals Financials
Rocket Pharmaceuticals (RCKT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $0.24 by 254.17 percent. This is a 40.32 percent increase over losses of $(0.62) per
Benzinga Newsdesk
PRO
Rocket Pharmaceuticals Q1 EPS $(0.42) Beats $(0.43) Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 25 percent increase over losses of $(0.56) per share
Benzinga Newsdesk
PRO
Rocket Pharmaceuticals Q4 EPS $(0.38) Beats $(0.44) Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.44) by 13.04 percent. This is a 38.71 percent increase over losses of $(0.62) per share
Benzinga Newsdesk
PRO
Rocket Pharmaceuticals Q3 EPS $(0.45) Beats $(0.52) Estimate
Benzinga Newsdesk
PRO
Rocket Pharmaceuticals Q2 EPS $(0.62) Misses $(0.56) Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.56) by 10.91 percent. This is a 16.22 percent increase over losses of $(0.74) per
Benzinga Newsdesk
Dow Surges Over 600 Points; US Durable Goods Orders Fall in April
Avi Kapoor
